|
Ms. Falberg has over 23 years of financial experience. Ms. Falberg joined Amgen a global biotechnology company in 1995 as Treasurer and advanced through a series of positions of increasing responsibility culminating in her appointment as Senior Vice President Finance and Chief Financial Officer in 1998. At Amgen over a period of almost seven years Ms. Falberg played a key role in shaping strategy as the company grew from $1.6 billion to $4.0 billion in revenues and from $7 billion to $70 billion in market capitalization. Prior to Amgen Ms. Falberg served as Vice President Chief Financial Officer and Treasurer of Applied Magnetics Corporation. After her retirement from Amgen she was a consultant to Inamed a medical device company (previously traded on the Nasdaq and acquired by Allergan for $3.2 billion) and briefly served as its interim Chief Financial Officer. She has served on the board of directors of VISX Human Genome Sciences and Fresh Del Monte Produce. Ms. Falberg received her M.B.A. and her B.A. in Economics from the University of California Los Angeles. Ms. Falberg is the Chairman of the Audit Committee. | 